Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Has Consensus Target Price of $9.60 According to Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $9.60.

Several equities research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sana Biotechnology in a report on Wednesday, October 21st. TD Cowen upgraded shares of Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. Bank of America decreased their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 14th. Finally, Wall Street Zen raised Sana Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday.

Institutional Trading of Sana Biotechnology

A number of hedge funds have recently bought and sold shares of the company. Alphabet Inc. purchased a new position in Sana Biotechnology in the second quarter worth about $9,816,000. Bank of New York Mellon Corp bought a new stake in shares of Sana Biotechnology during the 2nd quarter valued at about $1,667,000. Bank of America Corp DE purchased a new stake in shares of Sana Biotechnology during the 2nd quarter valued at about $20,062,000. Deutsche Bank AG purchased a new stake in shares of Sana Biotechnology during the 2nd quarter valued at about $2,251,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Sana Biotechnology during the 2nd quarter valued at about $35,662,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Stock Down 1.2%

Shares of NASDAQ SANA opened at $2.43 on Wednesday. The firm’s 50-day moving average price is $2.82 and its 200-day moving average price is $3.33. Sana Biotechnology has a 52-week low of $2.22 and a 52-week high of $5.49. The company has a market cap of $728.13 million, a PE ratio of -4.58 and a beta of 2.30.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, equities research analysts anticipate that Sana Biotechnology will post -0.62 EPS for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.